What is Epitalon?
Epitalon, also spelled Epithalon, appears in telomerase and aging discussions. The selected study concerns cultured cells rather than a lifespan trial.
Video overview · 3:24
Epitalon: Does It Really Lengthen Telomeres and Extend Lifespan? What the Research Shows
How epitalon differs from the pineal extract epithalamin, the cell studies behind the telomere claim, the mixed animal lifespan results, why no published study has measured telomeres or lifespan in people given it, and its FDA, compounding and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
Epitalon is a tiny lab-made peptide, just four amino acids long, sold online as an anti-aging peptide that lengthens telomeres and extends lifespan. The telomere results are real, but they come from cells in a dish. Here is what is actually known.
Epitalon, also spelled epithalon, is four amino acids: alanine, glutamic acid, aspartic acid and glycine. Researchers designed it from the makeup of epithalamin, an extract of cattle pineal glands. The two are often mixed up online, but one is a single defined peptide, and the other is a tissue extract with many components.
Here is the idea. Telomeres are protective caps on the ends of chromosomes, and they shorten as cells divide. In cultured human cells, epitalon switched on telomerase, the enzyme that rebuilds them, and the telomeres got longer. Whether that happens in a person, or helps anyone live longer, has never been measured.
In 2003 and 2004, human fibroblast cells treated with epitalon made telomerase and grew longer telomeres, and aging cells went on to divide ten more times than untreated cells. A 2025 study from a different group confirmed longer telomeres in normal human cells. But in two breast cancer cell lines, telomeres got longer too, through a different route.
The lifespan results come from animals, and they are mixed. In fruit flies, lifespan rose eleven to sixteen percent. In a lifelong study of female mice, average lifespan did not change, though the longest-lived tenth lived about thirteen percent longer. And in female rats on a normal light cycle, lifespan did not change at all.
In people, we found no published study that measured telomere length or lifespan after giving epitalon. The human longevity study most often quoted, of two hundred sixty-six older adults, tested epithalamin, the pineal extract, not epitalon. And the FDA says it found no clinical safety data for epitalon.
Epitalon is not FDA approved. The FDA warns that compounded epitalon may cause immune reactions from impurities, and its staff advised against allowing it in pharmacy compounding. In July 2026, the FDA's advisory committee voted to recommend it anyway, for insomnia, not aging, and that vote is advisory only. In sport, it is likely covered by the anti-doping ban on unapproved substances.
Does epitalon lengthen telomeres in people? Unproven: that has only been shown in cells. Does it extend lifespan? Unproven: the animal results are mixed, and no human study has tested it. Is the famous human longevity study about epitalon? No, it tested a pineal extract. And is it safe? Unknown: the FDA found no clinical safety data.
The bottom line: epitalon lengthens telomeres in cells in a dish, its animal lifespan results are mixed, and no published study has measured telomeres or lifespan in people given it. It is not approved, and its safety is unknown. For every study and source, see the epitalon profile on PepsRadar dot com.
Biological role or research focus
Telomere and cellular-aging research.
Telomere changes in cultured cells do not demonstrate a longer or healthier human lifespan.
Role reference: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. ↗
Names you may encounter
epithalon
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Experimental telomerase-related peptide
- Main research area
- Cellular aging biology
- Evidence featured
- Human cells in culture
- Source check
- October 4, 2026
Source: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. ↗
Quick answers
- Is Epitalon FDA approved?
- No. No FDA-approved drug contains Epitalon. Source ↗
- Is Epitalon safe?
- Epitalon is an unapproved synthetic tetrapeptide. FDA found no clinical data supporting its safety in people, and its evidence comes mainly from cell and animal studies. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Epitalon banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
- Has the FDA taken action over Epitalon?
- Yes. Our records list 4 FDA actions naming it, most recently on October 28, 2026: HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Telomerase experiment (2003) | Human cells in culture | Cultured human fetal fibroblasts without detectable baseline telomerase activity. |
Claim checks
Unproven Does epitalon lengthen telomeres and extend lifespan in humans?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human cells in culture · 2003
Telomerase experiment
Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.
- Population / model
- Cultured human fetal fibroblasts without detectable baseline telomerase activity.
- Study design
- Laboratory exposure followed by assays of telomerase expression, activity, and telomere length.
- Main finding
- The report described telomerase activation and telomere elongation.
- Limits & context
- “Human cells” does not mean human participants. This experiment measured cell biology, not cancer outcomes, functional aging, or lifespan in people.
Source: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Epitalon as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. ↗
International journal of molecular sciences · 2025 Mar 17 · Journal Article, Review
Read available full text ↗
Effect of epitalon on the lifespan increase in Drosophila melanogaster. ↗
Mechanisms of ageing and development · 2000 Dec 1 · Comparative Study, Journal Article
Peptides and Ageing. ↗
Neuro endocrinology letters · 2002 · Journal Article, Review
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. ↗
Frontiers in aging · 2026 · Journal Article, Review
Read available full text ↗
Risks & interactions
Epitalon is an unapproved synthetic tetrapeptide. FDA found no clinical data supporting its safety in people, and its evidence comes mainly from cell and animal studies.
FDA's 2026 review found no clinical safety data for epitalon. Older small reports from one research group describe use in patients but are not controlled safety studies. Effects of repeated exposure are unknown.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- FDA: possible immune reactions (immunogenicity) from aggregation and peptide impurities in compounded products
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA briefing document: epitalon (Pharmacy Compounding Advisory Committee, 2026) ↗ · FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · Epithalon and telomerase in human cells (2003) ↗
Safety evidence & remaining uncertainty
FDA identifies missing route-specific safety information. A cell-culture experiment cannot establish the consequences of systemic or repeated exposure.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Epitalon". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. FDA presented epitalon (free base and acetate) to its Pharmacy Compounding Advisory Committee on July 24, 2026, proposing that it NOT be added to the 503A bulks list. On October 28, 2026, HHS filed an interim enforcement discretion policy covering Epitalon (Federal Register 2026-22192): HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding it while rulemaking proceeds. That is not listing on the 503A bulks list and not FDA approval. source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
FDA actions
- HHS filed an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (Federal Register 2026-22192, published October 30, 2026; RIN 0910-ZD94). Epitalon is one of six peptides in its Appendix A (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500). HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding with these peptides while FDA develops the 503A bulks list by rulemaking. It is not an FDA approval, does not add Epitalon to the 503A bulks list, is not binding, and HHS may revisit it if a safety signal or quality problem arises. The comment period on regulations.gov closed on November 13, 2026 (docket HHS-OASH-2026-0496). (2026-10-28) source
- FDA presented epitalon (free base and acetate) to its Pharmacy Compounding Advisory Committee (July 24, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. The committee's vote is advisory; no final FDA decision found. (2026-07) source
- FDA warning letter to an outsourcing facility (GenoGenix) naming "Epithalon" among products with labeling violations. (2026-01-20) source
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing Epitalon among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
This profile presents a laboratory hypothesis. Demonstrating a cellular change does not establish prevention of age-related disease or a longevity indication.
Source: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
The cited experiment examined activation of telomerase and elongation of telomeres. These are features of cell maintenance and replication, not direct measurements of healthy aging.
Source: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. ↗
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- Telomere changes in cultured cells do not demonstrate a longer or healthier human lifespan.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Did this study show that people lived longer?
No. It used fetal fibroblast cultures and did not measure human lifespan.
Source: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. ↗
Is a longer telomere automatically a better health outcome?
No clinical outcome was measured here. A biomarker change must be linked to patient benefit and harms before that conclusion is justified.
Source: Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Which peptides can pharmacies compound now? The 2026 HHS peptide policy explained
HHS says it will not act against licensed 503A compounders using six peptides while FDA writes its bulks-list rules. That is not FDA approval, and FDA staff found little or no human data for any of the six.
Read the guide →
